The Central Asian Journal of Nephrology (ISSN 3105-4145) aims to provide a platform for the dissemination of high-quality research, clinical studies and expert opinions in the field of nephrology. It is dedicated to improving the understanding, prevention, diagnosis and treatment of kidney diseases in Central Asia and beyond. The journal aims to promote collaboration between researchers, clinicians and healthcare professionals to address the unique challenges in nephrology faced by the Central Asian region, because of its same cultural and environment factors, genetic background and similar healthcare models.

Call for Publications

The Central Asian Journal of Nephrology invites researchers from all over the world, clinicians, healthcare professionals, and policymakers to submit manuscripts that contribute to advancing knowledge and practice in nephrology, accommodating its regional focus and the specialized field of nephrology, while ensuring relevance to both local and international audiences.

We welcome original research, reviews, case reports, and methodological papers that explore all aspects of kidney health and disease. Topics of interest include, but are not limited to:

Prevention, diagnosis, and management of acute and chronic kidney diseases
Dialysis and renal transplantation
Basic science research in nephrology
Epidemiological studies on kidney disease burden
Public health and policy innovations in nephrology
Applications of data science, digital health, and AI in nephrology
Real-world evidence, patient-centered outcomes, and healthcare equity

The journal seeks to disseminate high-quality, interdisciplinary research that enhances clinical practice, informs policy, and promotes kidney health across Central Asia and beyond.

We encourage submissions that reflect regional insights, cross-national collaborations, and innovative approaches to addressing the growing challenges of kidney diseases.

Submit your manuscript today and join us in shaping the future of nephrology in Central Asia and beyond.

CURRENT ISSUE

Volume 2, Issue 2, 2026

(Ongoing)

Case Report

Beyond Iron Repletion: The Hypophosphatemia Risk of Ferric Carboxymaltose

Farah Alabbasi, Mohammad Elraggal, Raed Alenezi, Ali Alshaqaq

Central Asian Journal of Nephrology, 2(2), 2026, cajn014, https://doi.org/10.63946/cajn/18335

ABSTRACT: Post-bariatric surgery patients face higher risk of micronutrient malabsorption and often receive intravenous iron like Ferric carboxymaltose (FCM). Recent studies associate FCM with severe (serum phosphate levels < 1 mg/dL) and prolonged hypophosphatemia caused by elevated Fibroblast Growth Factor 23 (FGF23) levels, which reduces phosphate reabsorption in the kidneys via α-Klotho co-receptor. FCM, in particular, can therefore lead to notable and sustained FGF23-mediated hypophos-phatemia. We present a case of prolonged and severe hypophosphatemia secondary to fibroblast growth factor 23 (FGF23)-mediated phosphaturia following ferric carboxymaltose (FCM) administration in a post-bariatric surgery patient. This case underscores the complex interplay between intravenous iron therapy, phosphate metabolism, and altered absorption physiology following bariatric surgery. It highlights the need for clinicians to monitor phosphate levels after FCM administration, particularly in high-risk patients such as those with malabsorption.